“2024 was an important year of execution as it relates to our clinical development programs in cardiovascular inflammation and thyroid eye disease,” said Sandeep Kulkarni, CEO. “We are now transitioning into a potentially transformative year of data in 2025, leading off with topline data from our Phase 2 TRANQUILITY trial expected in the second quarter. Complemented by our strong balance sheet and with the support of our world-class team, we look forward to sharing our first data readouts this year and making further progress towards realizing the enormous standard-of-care changing potential of pacibekitug.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Robinhood initiated, MongoDB downgraded: Wall Street’s top analyst calls
- Wedbush bullish on Tourmaline Bio, initiates with an Outperform
- Tourmaline Bio initiated with an Outperform at Wedbush
- Tourmaline Bio initiated with an Outperform at LifeSci Capital
- Tourmaline Bio management to meet with Truist